Galvmed business plan

The project is exploring the potential efficacy of a vaccine to combat contagious bovine pleuropneumonia which is a major constraint to cattle production in many areas of sub-Saharan Africa where 18 countries are reported to be affected by this disease. GALV was founded in Earlier, in the early s,scoping work under the DFID Animal Health Programme AHP[4] identified the need for an organisation to promote the creation of a consortia to invest in research to produce livestock vaccines, diagnostics and other products for the control of tropical livestock diseases, which the private pharmaceutical sector was not funding at the time.

The stated purpose of the BMGF grant was to develop safe and effective drugs against drug-resistant AAT as well as a diagnostic test for field diagnosis of infection in cattle and to improve the quality control of existing trypanocidal drugs used by smallholder livestock keepers in sub-Saharan Africa.

The focus for phase 2 was diseases that affect primarily the cattle, sheep, goats and chickens of poor farmers in sub-Saharan Africa and South Asia.

They also aimed to develop data-driven decision making tools and to communicate, network and support advocacy and global access strategy requirements of project delivery. The objective was to develop a new robust field diagnostic tool for AAT, new trypanocidal drugs and to establish the basis for the development of a vaccine for AAT.

Its head office is located in Edinburgh, Scotland. GALVmed led the implementation of a VACNADA component to improve the capacity of eight African laboratories to make quality assured vaccines in more efficient ways that met internationally recognised quality standards and best practices.

East Coast fever ECF that affects cattle, Rift Valley fever RVF that affects cattle, sheep, goats, camels and also people, porcine cysticercosis, that affects pigs and also people, and Newcastle diseasethat affects poultry. Staff from selected national vaccine producing laboratories, identified through a needs assessment, received training in laboratory and vaccine operation management, had their laboratory facilities upgraded and technical support provided for the implementation of quality assurance and standardisation of the production process of selected vaccines.

GALVmed is currently working on 12 viral, bacterial and protozoal diseases that affect cattle, sheep and goats, pigs and poultry, some of which are zoonotic. It has more than active partnerships. The stated goal for phase 1 was to improve the health of livestock and increase food security galvmed business plan human health of poor livestock keepers in low-income countries.

In earlythis was amended to "protecting livestock, improving human lives" to reflect the increased emphasis on delivery and livelihoods.

The board provides strategic oversight and is in turn overseen by Members who are drawn from a wide range of public bodies, private institutions including pharmaceutical companies, and non-governmental organisations.

Two vaccines, one for the tick-borne cattle disease ECF and one emergency vaccine for the cattle, sheep and goat disease RVF, were reported to be already in wide use in Africa. Known as the PLSHL project, protecting livestock reflected the predominant focus on preventive veterinary medicines, especially vaccines, while saving human life indicated that two of the four key diseases GALVmed was targeting were zoonotic.

As a result, the AHP went on to facilitate the establishment of GALV with an appropriate legal and institutional framework and its first business plan. In addition, exploratory activities were undertaken on African swine fever.

The 12 diseases are: The PLSHL project also comprised funding to assess existing vaccines and diagnostics on a further three diseases: GALVmed is governed by a board made up of 11 trustees, recruited for their individual skills and experiences.

For these diseases, GALVmed and partners aimed to identify suitable mechanisms for the development of control tools vaccines, diagnostics and pharmaceuticals and to facilitate their access and adoption.

GALVmed has 43 staff members and long-term consultants in addition to advisors and contracted consultants.Gender in GALVmed’s present & future• Important themes for GALVmed which conceptualisation and formulation of gender strategies and implementation activities must bear in mind (& vice versa): – Business development, market development & commercialisation – Data, data, data (and more data!).

GALVmed; Founded: Type: Public-private partnership; Registered charity in Scotland, England and Wales AHP went on to facilitate the establishment of GALV with an appropriate legal and institutional framework and its first business plan. GALVmed has invested heavily in providing infrastructure and business and technical support to Website: Writing a Business Plan Georgia State SBDC 2 Why Write a Business Plan?

A Business Plan helps you evaluate the feasibility of a new business idea in an objective, critical, and unemotional way. A business plan is a written description of your business's future, a document that tells what you plan to do and how you plan to do it.

If you jot down a. Get inspiration on how to write a business plan. Our gallery of over + free business plan samples include: restaurants, online retail, health care, plus tons of business.

Keep in mind that a business plan is a living document and you can always start with a one-page plan and enlarge it with additional detail as required. You may be able to articulate the business overview, vision, objectives, and concise action items in a single page, but you might want more detail in the financial and marketing sections.

Galvmed business plan
Rated 5/5 based on 70 review